ANTI-IL-6R Polypeptides and Pharmaceutical Compositions Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2010/054764, filed Apr 12, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,748,581 | ANTI-IL-6R Polypeptides and Pharmaceutical Compositions Thereof In force · High confidence | Ablynx N.V. | In force | High confidence | ||
| US 8,962,805 | aNTI-6R POLYPEPTIDES AND COMPOSITIONS THEREOF In force · High confidence | Ablynx N.V. | In force | High confidence | ||
| US 9,181,350 | Nucleic Acids Encoding IL-6R-BINDING Polypeptides In force · High confidence | Ablynx N.V. | In force | High confidence | ||
| US 9,273,150 | Methods of Using IL-6R Antibodies to Block or Reduce Binding of IL-6 to IL-6R In force · High confidence | Ablynx N.V. | In force | High confidence | ||
| US 10,392,440 | Methods for the Preparation of Compounds Directed Against INTERLEUKIN-6 Receptor (IL-6R) In force · High confidence | Ablynx N.V. | In force | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.